Item 2.02 Results of Operations and Financial Condition.

Five Prime Therapeutics, Inc. ("FivePrime") is in the process of finalizing its financial results for the fiscal year ended December 31, 2020. Set forth below is a preliminary estimate of FivePrime's cash, cash equivalents and marketable securities as of December 31, 2020, based on information currently available as of the date of this Current Report on Form 8-K (this "Current Report").

FivePrime estimates that its cash, cash equivalents and marketable securities as of December 31, 2020 was approximately $288.5 million. FivePrime's actual consolidated cash, cash equivalents and marketable securities as of December 31, 2020 may differ from these estimates due to the completion of FivePrime's year-end closing and auditing procedures.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses